Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929619 | 0.89 | NOD1 (0.39) | NOD1GNPATFOLH1PTGS1GSTK1 | |
| SCHEMBL18104611 | 0.88 | HPGDS (0.44) | NOD1GNPATFOLH1TLR2ROCK2 | |
| SCHEMBL30440181 | 0.85 | ALB (0.48) | NOD1GNPATALBTLR2ROCK2 | |
| SCHEMBL31626331 | 0.85 | ALB (0.48) | NOD1GNPATALBTLR2ROCK2 | |
| SCHEMBL18106098 | 0.84 | MMP12 (0.47) | NOD1GNPATFOLH1PTGS1GSTK1 | |
| Formic Acid SCHEMBL29057396 | 0.82 | NOD1 (0.42) | NOD1TLR2 | |
| SCHEMBL929549 | 0.82 | PTGS1 (0.41) | NOD1GNPATFOLH1PTGS1GSTK1 | |
| Formic Acid SCHEMBL30439638 | 0.80 | ALB (0.45) | NOD1ALBTLR2ROCK2PRKACA | |
| SCHEMBL11112082 | 0.80 | FNTA (0.48) | NOD1 | |
| SCHEMBL17919599 | 0.78 | ALB (0.48) | NOD1ALBTLR2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | NOD1 4684/4885GNPAT 3899/4885C3AR1 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.